| Literature DB >> 31861740 |
José Enrique Iranzo-Cortés1, José María Montiel-Company1, Teresa Almerich-Torres1, Carlos Bellot-Arcís1, José Manuel Almerich-Silla1.
Abstract
OBJECTIVE: To analyse the published evidence of the validity of DIAGNDOdent and VistaProof in diagnosing carious depths in pre-cavitated lesions. Material and methods: A systematic review was carried out after identifying a total of 184 articles, including 27 concerning the qualitative review and a subsequent meta-analysis. The quality of the studies was evaluated by using the QUADAS-2 tool.Entities:
Keywords: DIAGNOdent; VistaProof; caries diagnosis; incipient caries; laser fluorescence
Year: 2019 PMID: 31861740 PMCID: PMC7019252 DOI: 10.3390/jcm9010020
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Flow diagram.
Results of the studies included in the review. Se:Sensitivity; Sp:Specifity; Az: Area Under ROC curve; the number indicates the examiner. Pri: Primary tooth; Per: Permanent tooth; D1: caries limited to enamel in histology; D3: caries in dentin in histology. * Histology, Rx o ICDAS when classified as sound by visual criteria (ICDAS = 0).
| Study | Examiners |
| In Vivo/In Vitro | Dentition | VistaProof Results | DIAGNOdent Results | Reference Test | |
|---|---|---|---|---|---|---|---|---|
| Rodrigues 2008 [ | 2 | 119 | In vitro | Per | D3: Se:0.86;Sp:0.63;Az:0.752 | D3:Se:0.78;Sp:0.56;Az:0.794 | Histology | |
| Diniz 2011 [ | 2 | 110 | In vitro | Per | D1:Se1:0.81;Sp1:0.50;Az1:0.73 | D1:Se1:0.50;Sp1:1.00;Az1:0.86 | Histology | |
| D3:Se1:0.55;Sp1:0.81;Az1:0.65 | D3:Se1:0.50;Sp1:0.73;Az1:0.64 | |||||||
| Jablonski-Momeni 2011a [ | 2 | 99 | In vitro | Per | D1:Se1:0.81;Sp1:0.40;Az1:0.77 | N/A | Histology | |
| D3:Se1:0.09;Sp1:0.97;Az1:0.81 Se2:0.04;Sp2:0.99;Az2:0.77 | ||||||||
| Jablonski-Momeni 2011b [ | 1 | 100 | In vitro | Per | N/A | D1:Se:0.82;Sp:0.48;Az:0.746 | Histology | |
| D3:Se:0.54;Sp:0.89;Az:0.786 | ||||||||
| Rodrigues 2011 [ | 2 | 97 | In vitro | Per | D1;Se:0.750;Sp:0.706;Az:0.760 | D1:Se:0.700;Sp:0.765;Az:0.720 | Histology | |
| D3:Se:0.963;Sp:0.700;Az:0.890 | D3:Se:0.630;Sp:0.886;Az:0.850 | |||||||
| Aktan 2012 [ | 2 | 129 | In vitro | Per | N/A | D1:Se1:0.65;Sp1:0.97;Az1:0.769 | Histology | |
| D3:Se1:0.33;Sp1:0.60;Az1:0.729 | ||||||||
| Diniz 2012 [ | 1 | 105 | In vivo | Per | D1:Se:0.74;Sp:0.80;Az:0.79 | D1:Se:0.89;Sp:0.80;Az:0.95 | Histology | |
| D3:Se:0.85;Sp:0.49;Az:0.72 | D3:Se:0.85;Sp:0.71;Az:0.79 | |||||||
| Jablonski-Momeni 2012a [ | 2 | 84 | In vitro | Per | N/A | D1:Se:0.690;Sp:0.923;Az:0.88 | Histology | |
| D3:Se:0.525;Sp:0.909;Az:0.88 | ||||||||
| Jablonski-Momeni 2012b [ | 2 | 82 | In vitro | Per | D1:Se1:0.65;Sp1:0.60; Az1:0.71 | D1:Se1:0.77;Sp1:0.40;Az1:0.72 | Histology | |
| D3:Se1:0.57;Sp1:0.66;Az1:0.65 | D3:Se1:0.71;Sp1:0.55;Az1:0.58 | |||||||
| Rechmann 2012 [ | 1 | 433 | In vivo | Per | N/A | Se:0.87;Sp:0.66;Az:0.87 | Cutoff points | |
| Seremidi 2012 [ | 4 | 107 | In vitro | Per | D1:Se:0.568;Sp:0.586;Az:0.577 | D1:Se:0.432;Sp:0.814;Az:0.623 | Histology | |
| D3;Se:0.876;Sp:0.125;Az:0.550 | D3:Se:0.795;Sp:0.750;Az:0.773 | |||||||
| Achilleos 2013 [ | 2 | 38 | In vitro | Per | Se1:0.97;Sp1:0.50;Az1:0.486 | Se1:0.75;Sp1:0.50;Az1:0.583 | Histology | |
| Jablonski-Momeni 2013 [ | 2 | 101 | In vitro | Per | D1:Se1:0.818;Sp1:0.933;Az1:0.93 | N/A | Histology | |
| D3:Se1:0.907;Sp1:0.776;Az1:0.93 | ||||||||
| Teo 2014 [ | 2 | 102 | In vivo/ In vitro | Pri | N/A | VivoD1:Se:0.87; Sp:0.44;Az:0.83 | VitroD1:Se:0.86; Sp:0.92;Az:0.92 | Histology |
| VivoD3:Se:0.95; Sp:0.64;Az:0.93 | VitroD3:Se:0.98; Sp:0.77;Az:0.93 | |||||||
| Jablonski-Momeni 2014 [ | 1 | 306 | In vivo | Per | D1:Se:0.922;Sp:0.460;Az:0.82 | N/A | * | |
| Sinanoglu 2014 [ | 2 | 217 | In Vivo | Per | N/A | Se1:0.89;Sp1:0.75;Az1:0.6407 | Histology | |
| Bussaneli 2015 [ | 2 | 102 | In vitro | Per | N/A | Se:0.662;Sp:0.821;Az:0.759 | Histology | |
| Melo 2015 [ | 1 | 32 | In vivo | Per | Se:0.964;Sp:1.000;Az:0.969 | Se:1.000;Sp:0.750;Az:0.969 | Histology | |
| Ozturk 2015 [ | 2 | 121 | In vitro | Per | N/A | Se1:0.86;Sp1:0.69;Az1:0.77 | Histology | |
| Theocharopoulou 2015 [ | 1 | 37 | In vivo | Pri/Per | N/A | Se:0.62;Sp:0.81;Az:N/A | ICDAS | |
| Castilho 2016 [ | 1 | 43 | In vivo | Per | N/A | Se:0.85;Sp:0.25;Az:0.55 | Histology | |
| Novaes 2016 [ | 2 | 99 | In vitro | Pri | D1:Se1:0.77;Sp1:0.82;Az1:0.79 | D1:Se1:0.96;Sp1:0.21;Az1:0.71 | Histology | |
| D3:Se1:0.52;Sp1:0.97;Az1:0.86 | D3:Se1:0.60; Sp1:0.82; Az1:0.76 | |||||||
| Peycheva 2016 [ | 2 | 45 | In vitro | Per | N/A | D3:Se:0.92;Sp:0.69;Az:N/A | Histology | |
| Iranzo-Cortés 2017 [ | 2 | 65 | In vitro | Per | N/A | Se:0.85;Sp:0.53;Az:0.73 | Histology | |
| Kockanat 2017 [ | 2 | 120 | In vivo/In vitro | Pri | N/A | VivoD1:Se1:0.89; Sp1:1.0;Az1:0.95 | VitroD1:Se1:0.92;Sp1:0.94;Az1:0.90 | Histology |
| VivoD3:Se1:0.81; Sp1:0.97;Az1:0.92 | VitroD3:Se1:0.78; Sp1:0.97;Az1:0.95 | |||||||
| Melo 2017 [ | 1 | 302 | In vivo | Per | Se:0.929;Sp:0.958;Az:0.965 | Se:0.924;Sp:0.927;Az:0.954 | Histology | |
| Iranzo-Cortés 2018 [ | 1 | 65 | In vitro | Per | Se1:0.70;Sp1:0.81;Az1:0.76 | N/A | Histology | |
Quality assessment of the studies following QUADAS-2 assessment tool. Risk: Low = √; Uncertain = ¿?; High = X.
| Study | Risk of Bias | Concerns Regarding Applicability | |||||
|---|---|---|---|---|---|---|---|
| Patient Selection | Index Test | Reference Standard | Flow and Timing | Patient Selection | Index Test | Reference Standard | |
| Rodrigues 2008 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Diniz 2011 [ | √ | √ | √ | √ | √ | √ | √ |
| Jablonski-Momeni 2011a [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Jablonski-Momeni 2011b [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Rodrigues 2011 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Aktan 2012 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Diniz 2012 [ | ¿? | ¿? | √ | √ | ¿? | ¿? | √ |
| Jablonski-Momeni 2012a [ | √ | √ | √ | √ | √ | √ | √ |
| Jablonski-Momeni 2012b [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Rechmann 2012 [ | √ | √ | X | √ | √ | √ | X |
| Seremidi 2012 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Achilleos 2013 [ | √ | √ | √ | √ | √ | √ | √ |
| Jablonski-Momeni 2013 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Teo 2014 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Jablonski-Momeni 2014 [ | ¿? | √ | X | √ | ¿? | √ | X |
| Sinanoglu 2014 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Bussaneli 2015 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Melo 2015 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Ozturk 2015 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Theocharopoulou 2015 [ | X | √ | X | √ | √ | √ | X |
| Castilho 2016 [ | X | √ | √ | √ | √ | √ | √ |
| Novaes 2016 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Peycheva 2016 [ | ¿? | √ | √ | √ | ¿? | √ | √ |
| Iranzo-Cortés 2017 [ | √ | √ | √ | √ | ¿? | √ | √ |
| Kockanat 2017 [ | √ | √ | √ | √ | √ | √ | √ |
| Melo 2017 [ | ¿? | √ | ¿? | √ | ¿? | √ | ¿? |
| Iranzo-Cortés 2018 [ | √ | √ | √ | √ | ¿? | √ | √ |
Figure 2Information is presented in graph form; the QUADAS-2 tool indicates the quality of the studies, analysing the probability of bias (a) and the concern about applicability (b).
Figure 3Forest Plot of sensitivity for DIAGNOdent.
Figure 4Forest Plot by sub-groups in vivo/in vitro of sensitivity for DIAGNOdent.
Figure 5Forest Plot for DIAGNOdent specificity.
Figure 6Forest Plot by sub-groups in vivo/in vitro for DIAGNOdent specificity.
Figure 7AUC Forest Plot for AUC for DIAGNOdent.
Figure 8AUC Forest Plot according to in vivo/in vitro sub-groups for DIAGNOdent.
Figure 9Funnel plot for the publication bias in the case of: sensitivity (a), specificity (b) and AUC (c) for DIAGNOdent.
Figure 10Forest Plot of VistaProof sensitivity.
Figure 11Forest Plot according to in vivo/in vitro subgroups for sensitivity when using VistaProof.
Figure 12Forest Plot for specificity when using VistaProof.
Figure 13Forest Plot for in vivo/in vitro sub-groups; sensitivity when using VistaProof.
Figure 14Forest Plot for AUC when using VistaProof.
Figure 15Forest Plot in vivo/in vitro sub-groups for AUC when using VistaProof.
Figure 16Funnel plot for the publication bias study in the cases of sensitivity (a), specificity (b) and AUC (c).
Sensitivity, specificity and AUC for all studies combined and for subgroups (CI-95%).
| DIAGNOdent | VistaProof | |||||
|---|---|---|---|---|---|---|
| All | Subgroup | All | Subgroup | |||
| In Vitro | In Vivo | In Vitro | In Vivo | |||
| Sensitivity | 0.772 | 0.714 | 0.852 | 0.813 | 0.747 | 0.912 |
| Specificity | 0.754 | 0.752 | 0.758 | 0.754 | 0.739 | 0.807 |
| AUC | 0.810 | 0.781 | 0.861 | 0.798 | 0.755 | 0.892 |